These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22122230)

  • 1. Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?
    Nalivaeva NN; Beckett C; Belyaev ND; Turner AJ
    J Neurochem; 2012 Jan; 120 Suppl 1():167-185. PubMed ID: 22122230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it?
    Nalivaeva NN; Belyaev ND; Zhuravin IA; Turner AJ
    Int J Alzheimers Dis; 2012; 2012():383796. PubMed ID: 22900228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease.
    Nalivaeva NN; Belyaev ND; Kerridge C; Turner AJ
    Front Aging Neurosci; 2014; 6():235. PubMed ID: 25278875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Insights into Epigenetic and Pharmacological Regulation of Amyloid-Degrading Enzymes.
    Nalivaeva NN; Belyaev ND; Turner AJ
    Neurochem Res; 2016 Mar; 41(3):620-30. PubMed ID: 26376806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
    Asai M; Kawakubo T; Mori R; Iwata N
    Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Powering Amyloid Beta Degrading Enzymes: A Possible Therapy for Alzheimer's Disease.
    Sikanyika NL; Parkington HC; Smith AI; Kuruppu S
    Neurochem Res; 2019 Jun; 44(6):1289-1296. PubMed ID: 30806879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy.
    Nalivaeva NN; Turner AJ
    Br J Pharmacol; 2019 Sep; 176(18):3447-3463. PubMed ID: 30710367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Ageing and Oxidative Stress in Regulation of Amyloid-Degrading Enzymes and Development of Neurodegeneration.
    Nalivaeva NN; Turner AJ
    Curr Aging Sci; 2017; 10(1):32-40. PubMed ID: 27834125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death.
    Leissring MA; Farris W; Chang AY; Walsh DM; Wu X; Sun X; Frosch MP; Selkoe DJ
    Neuron; 2003 Dec; 40(6):1087-93. PubMed ID: 14687544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications.
    Jha NK; Jha SK; Kumar D; Kejriwal N; Sharma R; Ambasta RK; Kumar P
    J Alzheimers Dis; 2015; 48(4):891-917. PubMed ID: 26444774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease.
    Hüttenrauch M; Baches S; Gerth J; Bayer TA; Weggen S; Wirths O
    J Alzheimers Dis; 2015; 44(4):1291-302. PubMed ID: 25408216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration.
    Turner AJ; Fisk L; Nalivaeva NN
    Ann N Y Acad Sci; 2004 Dec; 1035():1-20. PubMed ID: 15681797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease.
    Nalivaeva NN; Fisk LR; Belyaev ND; Turner AJ
    Curr Alzheimer Res; 2008 Apr; 5(2):212-24. PubMed ID: 18393806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?
    Carson JA; Turner AJ
    J Neurochem; 2002 Apr; 81(1):1-8. PubMed ID: 12067222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aβ-degrading enzymes: potential for treatment of Alzheimer disease.
    Miners JS; Barua N; Kehoe PG; Gill S; Love S
    J Neuropathol Exp Neurol; 2011 Nov; 70(11):944-59. PubMed ID: 22002425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology.
    Fukami S; Watanabe K; Iwata N; Haraoka J; Lu B; Gerard NP; Gerard C; Fraser P; Westaway D; St George-Hyslop P; Saido TC
    Neurosci Res; 2002 May; 43(1):39-56. PubMed ID: 12074840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NEP-like endopeptidases and Alzheimer's disease [corrected].
    Marr RA; Spencer BJ
    Curr Alzheimer Res; 2010 May; 7(3):223-9. PubMed ID: 20088804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the Amyloid Hypothesis in Alzheimer's Disease.
    Paroni G; Bisceglia P; Seripa D
    J Alzheimers Dis; 2019; 68(2):493-510. PubMed ID: 30883346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer's disease.
    Sakakibara Y; Sekiya M; Saito T; Saido TC; Iijima KM
    BMC Neurosci; 2019 Mar; 20(1):13. PubMed ID: 30894120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulating the Activity of Amyloid-Beta Degrading Enzymes: A Novel Approach for the Therapeutic Manipulation of Amyloid-Beta Levels.
    Kuruppu S; Rajapakse NW; Spicer AJ; Parkington HC; Smith AI
    J Alzheimers Dis; 2016 Oct; 54(3):891-895. PubMed ID: 27567865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.